SCHEMBL26918854

SCHEMBL26918854

N#Cc1cnc(NC2CCN(S(=O)(=O)c3ccc(Br)cc3)CC2)nc1Cl

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CCR6 P51684 10/20 0.52
▸ CDK2 P24941 6/20 0.46
▸ CCNE1 P24864 3/20 0.46
▸ CCNA2 P20248 3/20 0.45
▸ CCNK O75909 1/20 0.45
▸ CDK12 Q9NYV4 1/20 0.45
▸ CCNT1 O60563 2/20 0.44
▸ CDK1 P06493 2/20 0.44
▸ CDK4 P11802 2/20 0.44
▸ CCNB1 P14635 2/20 0.44
▸ CCND1 P24385 2/20 0.44
▸ CCND3 P30281 2/20 0.44
▸ CDK7 P50613 2/20 0.44
▸ CDK9 P50750 2/20 0.44
▸ CCNH P51946 2/20 0.44
▸ MNAT1 P51948 2/20 0.44
▸ CDK6 Q00534 2/20 0.44
▸ IKBKB O14920 3/20 0.43
▸ CHUK O15111 1/20 0.43
▸ MAPK8 P45983 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30496639 1.00 CCR6 (0.52) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL29763106 0.88 CCR6 (0.49) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL26919457 0.88 CCR6 (0.49) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL26918832 0.84 MERTK (0.48) CCR6CDK2CCNA2CCNKCDK12
SCHEMBL26918826 0.84 MERTK (0.48) CCR6CDK2CCNA2CCNKCDK12
SCHEMBL24477981 0.83 CDK2 (0.53) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL29631714 0.83 CDK2 (0.53) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL26918950 0.82 CCR6 (0.48) CCR6CDK2CCNE1CCNA2CCNK
SCHEMBL22901115 0.82 CCNE1 (0.55) CDK2CCNE1CCNT1CDK1CDK4
SCHEMBL22900808 0.82 CCNE1 (0.56) CCR6CDK2CCNE1CCNT1CDK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250009745-A1 CDK INHIBITOR SHANGHAI QILU PHARMACEUTICAL RESEARCH AND DEVELOPMENT CENTRE LTD. (CN) 2025-01-09 — — US disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 — — EP disclosed
EP-4289835-A1 CDK INHIBITOR Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. (CN) 2023-12-13 — — EP disclosed
CN-116472270-A CDK inhibitors 上海齐鲁制药研究中心有限公司 2023-07-21 — — CN disclosed
WO-2022166793-A1 CDK INHIBITOR 上海齐鲁制药研究中心有限公司 2022-08-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250009745-A1 CDK INHIBITOR CDK9, CDKL1, CDK6 CCR6 3523/4885CDK2 11/4885CCNE1 32/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback